Sudenga Staci L, Torres B Nelson, Silva Roberto, Villa Luisa L, Lazcano-Ponce Eduardo, Abrahamsen Martha, Baggio Maria Luiza, Salmeron Jorge, Quiterio Manuel, Giuliano Anna R
Division of Epidemiology, Vanderbilt University Medical Center, Nashville, Tennessee.
Center for Infection Research in Cancer, Moffitt Cancer Center, Tampa, Florida.
Cancer Epidemiol Biomarkers Prev. 2017 Jul;26(7):1043-1052. doi: 10.1158/1055-9965.EPI-17-0040. Epub 2017 Apr 26.
Male genital human papillomavirus (HPV) prevalence and incidence has been reported to vary by geographical location. Our objective was to assess the natural history of genital HPV by country among men with a median of 48 months of follow-up. Men ages 18-70 years were recruited from United States ( = 1,326), Mexico ( = 1,349), and Brazil ( = 1,410). Genital specimens were collected every 6 months and HPV genotyping identified 37 HPV genotypes. Prevalence of HPV was compared between the three countries using the Fisher exact test. Incidence rates and 95% confidence intervals were calculated. The median time to HPV clearance among men with an incident infection was estimated using the Kaplan-Meier method. The prevalence and incidence of the genital HPV types known to cause disease in males (HPV 16 and 6) was significantly higher among men from Brazil than men from Mexico. Prevalence and incidence of those genital HPV types in the United States varied between being comparable with those of Mexico or Brazil. Although genital HPV16 duration was significantly longer in Brazil ( = 0.04) compared with Mexico and the United States, HPV6 duration was shortest in Brazil ( = 0.03) compared with Mexico and the United States. Men in Brazil and Mexico often have similar, if not higher prevalence of HPV compared with men from the United States. Currently, there is no routine screening for genital HPV among males and while HPV is common in men, and most naturally clear the infection, a proportion of men do develop HPV-related diseases. Men may benefit from gender-neutral vaccine policies. .
据报道,男性生殖器人乳头瘤病毒(HPV)的患病率和发病率因地理位置而异。我们的目标是在中位随访时间为48个月的男性中,按国家评估生殖器HPV的自然史。年龄在18至70岁的男性分别来自美国(n = 1326)、墨西哥(n = 1349)和巴西(n = 1410)。每6个月收集一次生殖器标本,并通过HPV基因分型鉴定出37种HPV基因型。使用Fisher精确检验比较三个国家之间的HPV患病率。计算发病率和95%置信区间。采用Kaplan-Meier方法估计新发感染男性中HPV清除的中位时间。在已知可导致男性疾病的生殖器HPV类型(HPV 16和6)中,巴西男性的患病率和发病率显著高于墨西哥男性。美国这些生殖器HPV类型的患病率和发病率在与墨西哥或巴西相当之间有所不同。尽管与墨西哥和美国相比,巴西的生殖器HPV16持续时间显著更长(P = 0.04),但与墨西哥和美国相比,巴西的HPV6持续时间最短(P = 0.03)。与美国男性相比,巴西和墨西哥男性的HPV患病率通常相似,甚至更高。目前,男性中没有常规的生殖器HPV筛查,虽然HPV在男性中很常见,且大多数人会自然清除感染,但仍有一部分男性会患上与HPV相关的疾病。男性可能会从性别中立的疫苗政策中受益。